Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ALBEMARLE LABORATORIES

NPI: 1215572870 · DUNDALK, MD 21222 · Clinical Medical Laboratory · NPI assigned 11/07/2019

$9.52M
Total Medicaid Paid
100,109
Total Claims
70,855
Beneficiaries
2
Codes Billed
2020-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialDAWSON, FELIX (MANAGER)
NPI Enumeration Date11/07/2019

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 13,307 $1.21M
2021 17,287 $1.59M
2022 19,009 $1.77M
2023 20,979 $1.93M
2024 29,527 $3.02M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 87,229 64,769 $7.94M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 12,880 6,086 $1.58M